Cargando…

Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases

BACKGROUND: WHO has set a voluntary target of 80% availability of affordable essential medicines, including generics, to treat major non-communicable diseases (NCDs), in the public and private sectors of countries by 2025. We undertook a secondary analysis of data from 30 surveys in low- and middle-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ewen, Margaret, Zweekhorst, Marjolein, Regeer, Barbara, Laing, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295694/
https://www.ncbi.nlm.nih.gov/pubmed/28170413
http://dx.doi.org/10.1371/journal.pone.0171284
_version_ 1782505486496563200
author Ewen, Margaret
Zweekhorst, Marjolein
Regeer, Barbara
Laing, Richard
author_facet Ewen, Margaret
Zweekhorst, Marjolein
Regeer, Barbara
Laing, Richard
author_sort Ewen, Margaret
collection PubMed
description BACKGROUND: WHO has set a voluntary target of 80% availability of affordable essential medicines, including generics, to treat major non-communicable diseases (NCDs), in the public and private sectors of countries by 2025. We undertook a secondary analysis of data from 30 surveys in low- and middle-income countries, conducted from 2008–2015 using the World Health Organization (WHO)/Health Action International (HAI) medicine availability and price survey methodology, to establish a baseline for this target. METHODS: Data for 49 medicines (lowest priced generics and originator brands) to treat cardiovascular diseases (CVD), diabetes, chronic obstructive pulmonary diseases (COPD) and central nervous system (CNS) conditions were analysed to determine their availability in healthcare facilities and pharmacies, their affordability for those on low incomes (based on median patient prices of each medicine), and the percentage of medicines that were both available and affordable. Affordability was expressed as the number of days’ wages of the lowest-paid unskilled government worker needed to purchase 30 days’ supply using standard treatment regimens. Paying more than 1 days’ wages was considered unaffordable. FINDINGS: In low-income countries, 15.2% and 18.9% of lowest-priced generics met WHO’s target in the public and private sectors, respectively, and 2.6% and 5.2% of originator brands. In lower-middle income countries, 23.8% and 23.2% of lowest priced generics, and 0.8% and 1.4% of originator brands, met the target in the public and private sectors, respectively. In upper-middle income countries, the situation was better for generics but still suboptimal as 36.0% and 39.4% met the target in public and private sectors, respectively. For originator brands in upper-middle income countries, none reached the target in the public sector and 13.7% in the private sector. Across the therapeutic groups for lowest priced generics, CVD medicines in low-income countries (11.9%), and CNS medicines in lower-middle (10.2%) and upper-middle income countries (33.3%), were least available and affordable in the public sector. In the private sector for lowest priced generics, CNS medicines were least available and affordable in all three country income groups (11.4%, 5.8% and 29.3% in low-, lower-middle and upper-middle income countries respectively). INTERPRETATION: This data, which can act as a baseline for the WHO target, shows low availability and/or poor affordability is resulting in few essential NCD medicines meeting the target in low- and middle-income countries. In the era of Sustainable Development Goals, and as countries work to achieve Universal Health Coverage, increased commitments are needed by governments to improve the situation through the development of evidence-informed, nationally-contextualised interventions, with regular monitoring of NCD medicine availability, patient prices and affordability.
format Online
Article
Text
id pubmed-5295694
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-52956942017-02-17 Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases Ewen, Margaret Zweekhorst, Marjolein Regeer, Barbara Laing, Richard PLoS One Research Article BACKGROUND: WHO has set a voluntary target of 80% availability of affordable essential medicines, including generics, to treat major non-communicable diseases (NCDs), in the public and private sectors of countries by 2025. We undertook a secondary analysis of data from 30 surveys in low- and middle-income countries, conducted from 2008–2015 using the World Health Organization (WHO)/Health Action International (HAI) medicine availability and price survey methodology, to establish a baseline for this target. METHODS: Data for 49 medicines (lowest priced generics and originator brands) to treat cardiovascular diseases (CVD), diabetes, chronic obstructive pulmonary diseases (COPD) and central nervous system (CNS) conditions were analysed to determine their availability in healthcare facilities and pharmacies, their affordability for those on low incomes (based on median patient prices of each medicine), and the percentage of medicines that were both available and affordable. Affordability was expressed as the number of days’ wages of the lowest-paid unskilled government worker needed to purchase 30 days’ supply using standard treatment regimens. Paying more than 1 days’ wages was considered unaffordable. FINDINGS: In low-income countries, 15.2% and 18.9% of lowest-priced generics met WHO’s target in the public and private sectors, respectively, and 2.6% and 5.2% of originator brands. In lower-middle income countries, 23.8% and 23.2% of lowest priced generics, and 0.8% and 1.4% of originator brands, met the target in the public and private sectors, respectively. In upper-middle income countries, the situation was better for generics but still suboptimal as 36.0% and 39.4% met the target in public and private sectors, respectively. For originator brands in upper-middle income countries, none reached the target in the public sector and 13.7% in the private sector. Across the therapeutic groups for lowest priced generics, CVD medicines in low-income countries (11.9%), and CNS medicines in lower-middle (10.2%) and upper-middle income countries (33.3%), were least available and affordable in the public sector. In the private sector for lowest priced generics, CNS medicines were least available and affordable in all three country income groups (11.4%, 5.8% and 29.3% in low-, lower-middle and upper-middle income countries respectively). INTERPRETATION: This data, which can act as a baseline for the WHO target, shows low availability and/or poor affordability is resulting in few essential NCD medicines meeting the target in low- and middle-income countries. In the era of Sustainable Development Goals, and as countries work to achieve Universal Health Coverage, increased commitments are needed by governments to improve the situation through the development of evidence-informed, nationally-contextualised interventions, with regular monitoring of NCD medicine availability, patient prices and affordability. Public Library of Science 2017-02-07 /pmc/articles/PMC5295694/ /pubmed/28170413 http://dx.doi.org/10.1371/journal.pone.0171284 Text en © 2017 Ewen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ewen, Margaret
Zweekhorst, Marjolein
Regeer, Barbara
Laing, Richard
Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases
title Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases
title_full Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases
title_fullStr Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases
title_full_unstemmed Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases
title_short Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases
title_sort baseline assessment of who’s target for both availability and affordability of essential medicines to treat non-communicable diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295694/
https://www.ncbi.nlm.nih.gov/pubmed/28170413
http://dx.doi.org/10.1371/journal.pone.0171284
work_keys_str_mv AT ewenmargaret baselineassessmentofwhostargetforbothavailabilityandaffordabilityofessentialmedicinestotreatnoncommunicablediseases
AT zweekhorstmarjolein baselineassessmentofwhostargetforbothavailabilityandaffordabilityofessentialmedicinestotreatnoncommunicablediseases
AT regeerbarbara baselineassessmentofwhostargetforbothavailabilityandaffordabilityofessentialmedicinestotreatnoncommunicablediseases
AT laingrichard baselineassessmentofwhostargetforbothavailabilityandaffordabilityofessentialmedicinestotreatnoncommunicablediseases